English | Español

Pharmaceuticals

+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Analysts identify biotech firms as potential M&A targets amid active deal environment
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Researchers identify ZFP36L2 protein as key to colorectal cancer metastasis and treatment resistance
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Over one-third of biopharma workers stay for health insurance, poll shows
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Study finds link between hypothyroidism and increased risk of sleep apnea in São Paulo residents
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Five NextGen biotech winners go public, with most actively hiring this year
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

FDA advisory committees spark concerns over transparency and decision delays in rare disease drug reviews
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Lilly and FDA dispute retatrutide biologic status as regulatory filing approaches
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

KCNE gene family identified as key regulator in human electrical signaling and disease

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'